Kimia Biosciences Ltd
Incorporated in 1993, Kimia Biosciences Ltd
is in the business of Pharmaceutical products[1]
- Market Cap ₹ 241 Cr.
- Current Price ₹ 50.9
- High / Low ₹ 58.4 / 32.0
- Stock P/E
- Book Value ₹ 0.07
- Dividend Yield 0.00 %
- ROCE -4.16 %
- ROE -183 %
- Face Value ₹ 1.00
Pros
- Company's working capital requirements have reduced from 68.3 days to 47.2 days
Cons
- Stock is trading at 730 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 2.23% over past five years.
- Company has a low return on equity of -58.5% over last 3 years.
- Earnings include an other income of Rs.1.64 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 6 | 2 | 0 | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 105 | |
10 | 7 | 4 | 4 | 2 | 74 | 88 | 102 | 124 | 124 | 133 | 105 | |
Operating Profit | 2 | -0 | -2 | -3 | -1 | 2 | 6 | 4 | 8 | 1 | -5 | -0 |
OPM % | 16% | -5% | -110% | -1,779% | -56% | 3% | 6% | 4% | 6% | 0% | -4% | -0% |
0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 0 | 2 | |
Interest | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 5 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 3 |
Profit before tax | 1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 6 | -5 | -12 | -7 |
Tax % | 6% | 1% | -1% | -0% | 8% | -4% | -1% | -13% | 8% | 26% | 25% | 26% |
1 | -1 | -2 | -4 | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -5 | |
EPS in Rs | 1.71 | -1.06 | -2.30 | -5.48 | -1.26 | 2.26 | 2.64 | 0.30 | 1.08 | -0.78 | -1.98 | -1.12 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 32% |
5 Years: | 2% |
3 Years: | -8% |
TTM: | -18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 36% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 2% |
1 Year: | 37% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | -20% |
3 Years: | -58% |
Last Year: | -183% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 7 | 7 | 7 | 7 | 7 | 1 | 1 | 5 | 5 | 5 | 5 | 5 |
Reserves | -5 | -6 | -7 | -11 | -12 | -2 | 2 | 9 | 14 | 10 | 1 | -4 |
Preference Capital | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
1 | 0 | 1 | 7 | 14 | 33 | 31 | 34 | 45 | 41 | 53 | 44 | |
2 | 3 | 4 | 1 | 3 | 25 | 31 | 38 | 43 | 54 | 63 | 56 | |
Total Liabilities | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 |
4 | 4 | 3 | 3 | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 32 | |
CWIP | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 6 | 6 | 0 | 1 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 2 | 1 | 1 | 2 | 43 | 48 | 62 | 72 | 74 | 87 | 68 | |
Total Assets | 6 | 6 | 5 | 4 | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | 0 | -6 | -1 | -7 | -3 | 0 | 6 | 8 | -7 | 15 | |
-1 | -0 | 0 | -0 | -6 | -2 | -2 | -9 | -14 | -1 | -3 | -1 | |
-1 | -0 | -0 | 6 | 7 | 10 | 4 | 8 | 8 | -8 | 10 | -13 | |
Net Cash Flow | -0 | -0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 41 | 22 | 56 | 173 | 20 | 141 | 113 | 128 | 115 | 88 | 87 | 96 |
Inventory Days | 75 | 50 | 319 | 615 | 59 | 83 | 92 | 89 | 146 | 183 | 149 | |
Days Payable | 988 | 667 | 91 | 511 | 120 | 91 | 121 | 116 | 159 | 177 | 194 | |
Cash Conversion Cycle | 41 | -891 | -560 | 401 | 124 | 80 | 105 | 100 | 88 | 76 | 93 | 51 |
Working Capital Days | -10 | -58 | -530 | -173 | -1,358 | 70 | 83 | 94 | 98 | 78 | 79 | 47 |
ROCE % | 46% | -25% | -127% | -188% | -10% | 10% | 17% | 9% | 16% | -2% | -12% |
Documents
Announcements
- Closure of Trading Window 29 Jun
-
Information Under Regulation 30 Of SEBI (LODR), Regulations 2015.
28 Jun - Dear Sir/ Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the Board of the Company at their meeting …
- Board Meeting Outcome for Outcome Of Board Meeting. 28 Jun
- Board Meeting Intimation for Intimation Of Board Meeting 22 Jun
-
Board Meeting Outcome for Filing Of Declaration Of Unmodified Opinion.
14 Jun - The declaration of an unmodified opinion was inadvertently missed out due to technical snag during the filing process. We deeply regret this insight and any …
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Profile:[1][2]
Company manufactures Active Pharmaceuticals Ingredients. It has commercialized 25+ products with 9-10 molecules under development